赛升药业(300485) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥92,536,534.42, a decrease of 15.52% compared to ¥109,535,330.56 in the same period last year[4] - Net profit attributable to shareholders was ¥39,970,025.94, representing a significant increase of 120.97% from a loss of ¥190,617,604.88 in the previous year[4] - Basic and diluted earnings per share were both ¥0.0830, up 120.98% from a loss of ¥0.3957 per share in the previous year[4] - The company's total profit for the quarter was ¥47,504,454.06, a 121.11% increase from a loss of ¥225,040,253.45 in the same period last year[8] - The total comprehensive income for the first quarter of 2025 was CNY 38,892,408.64, a 120.23% increase compared to the same period in 2024[9] - The net profit attributable to the parent company reached CNY 39,917,502.64, reflecting a 120.95% increase year-over-year[9] - The company reported a net profit of ¥38,944,931.94, compared to a net loss of ¥192,345,921.24 in the previous period, indicating a significant turnaround in performance[20] - Operating profit was ¥47,375,395.14, while the previous period showed an operating loss of ¥225,039,153.45, reflecting improved operational efficiency[20] Cash Flow and Investments - The net cash flow from operating activities decreased by 74.63% to ¥10,683,764.62 from ¥42,114,786.47 in the same period last year[4] - Cash and cash equivalents decreased by 52.99% to CNY 59,346,661.92 from CNY 126,240,055.05 at the end of the previous year[9] - The company reported a 92.49% decrease in cash received from operating activities, totaling CNY 102,289.85, primarily due to the absence of government subsidies received in the previous year[9] - Operating cash flow for the first quarter was CNY 99,495,887.84, up 38.21% from CNY 71,989,356.62 in the same period last year[9] - The company recorded cash inflows from investment activities of ¥471,008,667.12, significantly higher than ¥164,833,714.82 in the previous period, indicating aggressive investment strategies[22] - The net cash flow from investment activities was -¥26,563,589.71, an improvement from -¥36,081,201.81 in the previous period, suggesting better management of investment cash flows[22] Assets and Liabilities - Total assets increased by 1.03% to ¥3,588,460,056.06 from ¥3,551,848,565.47 at the end of the previous year[4] - Current assets totaled ¥1,737,109,249.51, up from ¥1,711,643,897.26, reflecting an increase of 1.5%[16] - Non-current assets rose to ¥1,851,350,806.55 from ¥1,840,204,668.21, showing an increase of 0.8%[16] - Total liabilities decreased to ¥164,200,091.96 from ¥166,481,010.01, a decline of 1.4%[16] - The company's retained earnings increased to ¥1,823,350,235.01 from ¥1,783,380,209.07, an increase of 2.2%[17] - The total equity attributable to shareholders rose to ¥3,397,029,455.23 from ¥3,357,111,952.59, reflecting an increase of 1.2%[17] Expenses - The company reported a significant decrease in sales expenses by 30.89% to ¥29,937,487.70 from ¥43,319,060.18 in the previous year, primarily due to reduced marketing costs[8] - Total operating costs decreased to ¥90,214,129.14 from ¥103,930,716.38, reflecting a reduction of 13.2%[19] - Research and development expenses increased to ¥11,888,734.88, up from ¥9,168,151.11, indicating a rise of 29.6%[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 25,384[11] - The largest shareholder, Ma Xie, holds 49.51% of the shares, totaling 238,464,000 shares[11] Other Information - The company did not report any significant new product launches or technological advancements during this period[20]